Pharmacokinetic properties of tramadol and M1 metabolite in Northeast Brazilian donkeys (Equus asinus)

There is currently little information available on the pharmacokinetics and pharmacodynamics of the analgesic opioid tramadol when used in the veterinary medicine of domestic species. In this study, we aimed to determine the pharmacokinetics of tramadol and its active metabolite M1 following intravenous administration of 2 (T2) and 4 (T4) mg/kg to Northeast Brazilian donkeys. Tramadol and M1 plasma levels were quantified using a validated liquid chromatography-tandem mass spectrometry method. We found that plasma levels of tramadol and M1 were higher than those reported as clinically meaningful in humans for at least 3 hr. However, the pharmacokinetic parameter calculation corrected by dose analysis identified no proportional increase with dose for the AUC of tramadol (T2: 2,663 +/- 1,827 vs. T4: 2,964 +/- 1,038 ng*h/ml) and M1 (T2: 378 +/- 237 vs. T4: 345 +/- 142 ng*h/ml). This finding appears to be attributable to a significant increase in clearance and a reduction in the terminal half-life of tramadol. The frequency of adverse effects observed at the higher dose indicates that 2 mg/kg administered intravenously would be suitable for donkeys. Clinical studies are required to determine the implications of these observations regarding the pharmacodynamic response to tramadol in Northeast Brazilian donkeys.

Automated summary

This study aimed to determine the pharmacokinetics of tramadol and its metabolite M1 in donkeys, finding that plasma levels of tramadol and M1 were higher than clinically meaningful levels in humans after intravenous administration of 2 and 4 mg/kg. However, the AUC did not increase proportionally with dose. Higher dose led to adverse effects, recommending 2 mg/kg intravenous tramadol for donkeys. Further clinical studies are needed to understand the pharmacodynamic response to tramadol in Northeast Brazilian donkeys.